Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
|
EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): Miscellaneous
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2:00 PM GMT, 3:00 PM CEST) Milan, Italy and Morristown, NJ, USA – June 18, 2024 - Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00-11:00 AM EDT. This comprehensive research and investor update event will focus on Newron’s clinical, scientific and commercial plans for evenamide for chronic and treatment-resistant schizophrenia. Three of the leading KOLs in neuroscience and schizophrenia will review Newron’s Phase III evenamide program and explore the unmet needs, new concepts and recent neurobiological findings for treating poor responders and patients with treatment-resistant schizophrenia (TRS). These leading experts in psychiatry and schizophrenia are: Anthony Grace, Ph.D., is Editor-in-Chief, International Journal of Neuropsychopharmacology, Distinguished Professor of Neuroscience, and Professor of Psychiatry and Psychology at the University of Pittsburgh. Dr. Grace will present breakthrough pre-clinical data on treatment-resistant schizophrenia: Evenamide can exert unique efficacy in schizophrenia by targeting the site of pathology: preclinical evidence supports effects seen in patients with TRS John Kane, M.D., Co-Director & Professor, Institute of Behavioural Science, Feinstein Institutes for Medical Research, and Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. One of the leading researchers in the field of schizophrenia, Dr. Kane will address the topic: Difficult to treat, poorly responding patients with schizophrenia; new, unique results with evenamide offer new hope for these patients Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry at the Semel Institute of Neuroscience & Human Behavior at UCLA and the Director of the Section on Psychosis at the UCLA Neuropsychiatric Institute. Dr. Marder's research has focused on the treatment of schizophrenia and the pharmacology of antipsychotic drugs and he will present: New Hope for Patients with Treatment-Resistant Schizophrenia; Unique Results with Evenamide, a Glutamate Modulator, as an Add-On Medication Stefan Weber, Chief Executive Officer and Ravi Anand, M.D., Chief Medical Officer of Newron will host the event, and will also present updates on evenamide’s clinical and registration program. The event will be held at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00 - 11:00 AM EDT. Institutional investors, business partners, analysts and media representatives who are interested in attending in person, or virtually, must pre-register here (https://event.webcasts.com/starthere.jsp?ei=1674805&tp_key=06b6bdbd3e). For any additional information, please email newron@lavoiehealthscience.com. International telephone access to the Investor Day conference is also available at the following numbers: Switzerland/Europe: +41 (0)800 835 525 United Kingdom: +44 (0)800 756 3429 Japan: +81 00 531 161 384 United States: +1 (877) 407 8029 To ensure a timely connection, users are recommended to dial in at least 10 minutes prior to the scheduled conference. The webcast will be archived on the Company’s website for one month after the date of the event. About evenamide Evenamide, an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of ineffective doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide benefit in patients who are poor responders to current APs, including clozapine. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com For more information, please contact: UK/Europe Switzerland Germany/Europe USA
Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
18.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Newron Pharmaceuticals S.p.A. |
| via Antonio Meucci 3 | |
| 20091 Bresso | |
| Italy | |
| Phone: | +39 02 610 3461 |
| Fax: | +39 02 610 34654 |
| E-mail: | pr@newron.com |
| Internet: | www.newron.com |
| ISIN: | IT0004147952 |
| WKN: | A0LF18 |
| Listed: | Regulated Unofficial Market in Dusseldorf (Primärmarkt); London, SIX |
| EQS News ID: | 1928025 |
| End of News | EQS News Service |
|
|
1928025 18.06.2024 CET/CEST
